Market Research

Fragment Based Drug Discovery Market

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 180 Pages Transparency Market Research Pvt. Ltd. July, 2023 TNPR18164197
Best Price Guarantee
Price from $5,795
Length 180 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date July, 2023
SKU TNPR18164197

Fragment Based Drug Discovery Market (Component: Fragment Screening and Fragment Optimization; End-user: Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, and Contract Research Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Fragment Based Drug Discovery Market – Scope of Report

TMR’s report on the global fragment based drug discovery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global fragment based drug discovery market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fragment based drug discovery market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the fragment based drug discovery market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global fragment based drug discovery market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global fragment based drug discovery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global fragment based drug discovery market.

The report delves into the competitive landscape of the global fragment based drug discovery market. Key players operating in the global fragment based drug discovery market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global fragment based drug discovery market profiled in this report.

Key Questions Answered in Global Fragment Based Drug Discovery Market Report
  • What is the sales/revenue generated by fragment based drug discovery across all regions during the forecast period?
  • What are the opportunities in the global fragment based drug discovery market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Fragment Based Drug Discovery Market – Research Objectives and Research Approach

The comprehensive report on the global fragment based drug discovery market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global fragment based drug discovery market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global fragment based drug discovery market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fragment Based Drug Discovery Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fragment Based Drug Discovery Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Key Industry Events
5.3. Regulatory Scenario by Region/Globally
5.4. Major Research Institutes Involved
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Component, 2017-2031
6.3.1. Fragment Screening
6.3.1.1. Biophysical Techniques
6.3.1.1.1. NMR Spectroscopy
6.3.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
6.3.1.1.3. Fluorescence Polarization
6.3.1.1.4. Isothermal Titration Calorimetry
6.3.1.1.5. X-ray Crystallography
6.3.1.1.6. Surface Plasmon Resonance (SPR)
6.3.1.1.7. Bilayer Interferometry
6.3.1.1.8. Mass Spectrometry (MS)
6.3.1.1.9. Capillary Electrophoresis
6.3.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
6.3.1.1.11. Other Assays (Biochemical)
6.3.1.2. Non-biophysical Techniques
6.3.2. Fragment Optimization
6.4. Market Attractiveness Analysis, by Component
7. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Oncology
7.3.2. Central Nervous System (CNS) Disorders
7.3.3. Infectious Diseases
7.3.4. Cardiovascular Diseases
7.3.5. Metabolic Disorders
7.3.6. Inflammation & Autoimmune Diseases
7.4. Market Attractiveness Analysis, by Application
8. Global Fragment Based Drug Discovery Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Academic & Research Institutions
8.3.2. Pharmaceutical & Biotechnology Companies
8.3.3. Contract Research Organizations (CROs)
8.4. Market Attractiveness Analysis, by End-user
9. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Global Fragment Based Drug Discovery Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Component, 2017-2031
10.2.1. Fragment Screening
10.2.1.1. Biophysical Techniques
10.2.1.1.1. NMR Spectroscopy
10.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
10.2.1.1.3. Fluorescence Polarization
10.2.1.1.4. Isothermal Titration Calorimetry
10.2.1.1.5. X-ray Crystallography
10.2.1.1.6. Surface Plasmon Resonance (SPR)
10.2.1.1.7. Bilayer Interferometry
10.2.1.1.8. Mass Spectrometry (MS)
10.2.1.1.9. Capillary Electrophoresis
10.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
10.2.1.1.11. Other Assays (Biochemical)
10.2.1.2. Non-biophysical Techniques
10.2.2. Fragment Optimization
10.3. Market Value Forecast, by Application, 2017-2031
10.3.1. Oncology
10.3.2. Central Nervous System (CNS) Disorders
10.3.3. Infectious Diseases
10.3.4. Cardiovascular Diseases
10.3.5. Metabolic Disorders
10.3.6. Inflammation & Autoimmune Diseases
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Academic & Research Institutions
10.4.2. Pharmaceutical & Biotechnology Companies
10.4.3. Contract Research Organizations (CROs)
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Component
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Global Fragment Based Drug Discovery Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Component, 2017-2031
11.2.1. Fragment Screening
11.2.1.1. Biophysical Techniques
11.2.1.1.1. NMR Spectroscopy
11.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
11.2.1.1.3. Fluorescence Polarization
11.2.1.1.4. Isothermal Titration Calorimetry
11.2.1.1.5. X-ray Crystallography
11.2.1.1.6. Surface Plasmon Resonance (SPR)
11.2.1.1.7. Bilayer Interferometry
11.2.1.1.8. Mass Spectrometry (MS)
11.2.1.1.9. Capillary Electrophoresis
11.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
11.2.1.1.11. Other Assays (Biochemical)
11.2.1.2. Non-biophysical Techniques
11.2.2. Fragment Optimization
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Oncology
11.3.2. Central Nervous System (CNS) Disorders
11.3.3. Infectious Diseases
11.3.4. Cardiovascular Diseases
11.3.5. Metabolic Disorders
11.3.6. Inflammation & Autoimmune Diseases
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Academic & Research Institutions
11.4.2. Pharmaceutical & Biotechnology Companies
11.4.3. Contract Research Organizations (CROs)
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Component
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Global Fragment Based Drug Discovery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Component, 2017-2031
12.2.1. Fragment Screening
12.2.1.1. Biophysical Techniques
12.2.1.1.1. NMR Spectroscopy
12.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
12.2.1.1.3. Fluorescence Polarization
12.2.1.1.4. Isothermal Titration Calorimetry
12.2.1.1.5. X-ray Crystallography
12.2.1.1.6. Surface Plasmon Resonance (SPR)
12.2.1.1.7. Bilayer Interferometry
12.2.1.1.8. Mass Spectrometry (MS)
12.2.1.1.9. Capillary Electrophoresis
12.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
12.2.1.1.11. Other Assays (Biochemical)
12.2.1.2. Non-biophysical Techniques
12.2.2. Fragment Optimization
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Oncology
12.3.2. Central Nervous System (CNS) Disorders
12.3.3. Infectious Diseases
12.3.4. Cardiovascular Diseases
12.3.5. Metabolic Disorders
12.3.6. Inflammation & Autoimmune Diseases
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Academic & Research Institutions
12.4.2. Pharmaceutical & Biotechnology Companies
12.4.3. Contract Research Organizations (CROs)
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Component
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Global Fragment Based Drug Discovery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Component, 2017-2031
13.2.1. Fragment Screening
13.2.1.1. Biophysical Techniques
13.2.1.1.1. NMR Spectroscopy
13.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
13.2.1.1.3. Fluorescence Polarization
13.2.1.1.4. Isothermal Titration Calorimetry
13.2.1.1.5. X-ray Crystallography
13.2.1.1.6. Surface Plasmon Resonance (SPR)
13.2.1.1.7. Bilayer Interferometry
13.2.1.1.8. Mass Spectrometry (MS)
13.2.1.1.9. Capillary Electrophoresis
13.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
13.2.1.1.11. Other Assays (Biochemical)
13.2.1.2. Non-biophysical Techniques
13.2.2. Fragment Optimization
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Oncology
13.3.2. Central Nervous System (CNS) Disorders
13.3.3. Infectious Diseases
13.3.4. Cardiovascular Diseases
13.3.5. Metabolic Disorders
13.3.6. Inflammation & Autoimmune Diseases
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Academic & Research Institutions
13.4.2. Pharmaceutical & Biotechnology Companies
13.4.3. Contract Research Organizations (CROs)
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Component
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Global Fragment Based Drug Discovery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Component, 2017-2031
14.2.1. Fragment Screening
14.2.1.1. Biophysical Techniques
14.2.1.1.1. NMR Spectroscopy
14.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
14.2.1.1.3. Fluorescence Polarization
14.2.1.1.4. Isothermal Titration Calorimetry
14.2.1.1.5. X-ray Crystallography
14.2.1.1.6. Surface Plasmon Resonance (SPR)
14.2.1.1.7. Bilayer Interferometry
14.2.1.1.8. Mass Spectrometry (MS)
14.2.1.1.9. Capillary Electrophoresis
14.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
14.2.1.1.11. Other Assays (Biochemical)
14.2.1.2. Non-biophysical Techniques
14.2.2. Fragment Optimization
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Oncology
14.3.2. Central Nervous System (CNS) Disorders
14.3.3. Infectious Diseases
14.3.4. Cardiovascular Diseases
14.3.5. Metabolic Disorders
14.3.6. Inflammation & Autoimmune Diseases
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Academic & Research Institutions
14.4.2. Pharmaceutical & Biotechnology Companies
14.4.3. Contract Research Organizations (CROs)
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Component
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Alveus Pharmaceuticals Pvt. Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Astex Pharmaceuticals
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Charles River Laboratories International, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Beactica AB
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Emerald BioStructures, Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Crown Bioscience, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Evotec AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Proteros Fragments GmbH
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Kinetic Discovery Limited
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Sprint Bioscience
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Sygnature Discovery
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Structure Based Design, Inc.
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings